| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Genencor International, Inc. |
| 925 Page Mill Road, Palo Alto, CA 94304 * (650) 846-7500 |
| Business Description | The company is a global leader in the development of genetically based biotechnology product using an integrated suite of technology platforms, including gene discovery and functional genomics, molecular evolution and design, and human immunology. |
| Offering Information Company has | |||
| Trading As | GCOR (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 5/5/00 |
| Domestic Shares Offered | 7,000,000 | Offer Date | 7/27/00 |
| Foreign Shares Offered | 0 | Filing Range | $16.00 - $18.00 |
| Company Shares | 7,000,000 | Offer Price | $18.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.260 |
| Gross Proceeds | $126,000,000 | Selling | $0.750 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 58,860,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Merrill Lynch & Co. | Lead Manager | (212) 449-4600 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| CS First Boston | Co-manager | (212) 325-2000 |
| Salomon Smith Barney | Co-manager | (212) 723-7300 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 |
| Revenues | 215.113 | 259.992 | 310.342 | 289.111 | 316.602 | 74.866 | 79.699 |
| Income from Oper. | 17.306 | 14.077 | 41.826 | 26.038 | 32.938 | 9.354 | 12.618 |
| Net Income | 3.797 | 0.133 | 24.433 | 15.021 | 17.907 | 5.396 | 16.864 |
| E.P.S | -0.030 | -0.070 | 0.170 | 0.080 | 0.110 | 0.040 | 0.150 |
| Revenue Growth (%) | 20.86 | 19.37 | -6.84 | 9.509 | 6.46 | ||
| Net Income Growth (%) | -96.50 | 18,270.68 | -38.52 | 19.21 | 212.53 | ||
| Oper. Profit Margin (%) | 8.05 | 5.41 | 13.48 | 9.01 | 10.40 | 15.83 | 12.49 |
| Net Profit Margin (%) | 1.77 | 0.05 | 7.87 | 5.20 | 5.66 | 21.16 | 7.21 |
| Cash Flow - Oper. | 58.18 | 10.10 | 3.44 | ||||
| Cash Flow - Inv. | -20.08 | 0.96 | 12.29 | ||||
| Cash Flow - Fin. | -9.71 | -1.00 | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 509.42 | Current Assets | 165.52 | Current Ratio | 2.49 |
| Total Liab. | 386.04 | Current Liab. | 66.56 | Debt Ratio | 75.78% |
| Total Equity | 123.38 | Working Cap. | 98.96 | Debt to Equity Ratio | 3.13 |
| Cash | 53.86 | Return on Assets | 3.31% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, for capital expenditures, to finance possible acquisitions and for working capital and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Latham & Watkins |
| Bank's Law Firm | Debevoise & Plimpton |
| Registrar/Transfer Agent | Bank of New York |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Eastman Chemical Company | 48.20 | |
| Danisco | 48.20 | |
| Note: represents ownership of 5% or more prior to the offering. | ||